Literature DB >> 3521484

Evaluation of pefloxacin in experimental Escherichia coli meningitis.

A M Shibl, C J Hackbarth, M A Sande.   

Abstract

The therapeutic efficacy of the fluoroquinolone pefloxacin mesylate was compared with those of cefotaxime and chloramphenicol in a rabbit model of Escherichia coli meningitis. The mean percent penetration (+/- the standard deviation) of pefloxacin (range, 1 to 30 mg/kg per h) into cerebrospinal fluid of infected rabbits was 51.3 +/- 14.0 compared with 11.1 +/- 1.0 for cefotaxime (100 mg/kg per h) and 22.3 +/- 1.5 for chloramphenicol (60 mg/kg per h). The rate of bacterial killing (delta log10 CFU/ml per h) did not change over a dosage range of 1 to 15 mg/kg per h (-0.37 +/- 0.15, 20% sterile). At 30 mg/kg per h, the rate achieved (-0.77 +/- 0.18, 100% sterile) was comparable to that of cefotaxime (-0.88 +/- 0.23, 100% sterile) and superior to that of chloramphenicol (-0.10 +/- 0.14, 0% sterile).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3521484      PMCID: PMC180404          DOI: 10.1128/AAC.29.3.409

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  The rate of bacteriologic response to antimicrobial therapy in neonatal meningitis.

Authors:  G H McCracken
Journal:  Am J Dis Child       Date:  1972-06

Review 2.  Principles in the treatment of bacterial meningitis.

Authors:  M G Täuber; M A Sande
Journal:  Am J Med       Date:  1984-05-15       Impact factor: 4.965

3.  [Structure-activity relationships in the quinolone group: antibacterial activity of two new compounds (author's transl)].

Authors:  M Thibault; B Koumaré; C J Soussy; J Duval
Journal:  Ann Microbiol (Paris)       Date:  1981 May-Jun

4.  Pefloxacin therapy for experimental endocarditis caused by methicillin-susceptible or methicillin-resistant strains of Staphylococcus aureus.

Authors:  P M Sullam; M G Täuber; C J Hackbarth; H F Chambers; K G Scott; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

5.  Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives.

Authors:  R G Dacey; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191

6.  In vitro antibacterial activity of three new quinolone derivatives: rosoxacin, norfloxacin, pefloxacin.

Authors:  M O Husson; D Izard; H Leclerc
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1984-12

7.  Influence of the developmental state of valvular lesions on the antimicrobial activity of cefotaxime in experimental enterococcal infections.

Authors:  P M Sullam; T A Drake; M G Täuber; C J Hackbarth; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

8.  Penetration of pefloxacin into cerebrospinal fluid of patients with meningitis.

Authors:  M Wolff; B Regnier; C Daldoss; M Nkam; F Vachon
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

9.  Correlation of in vitro time-kill curves and kinetics of bacterial killing in cerebrospinal fluid during ceftriaxone therapy of experimental Escherichia coli meningitis.

Authors:  J M Decazes; J D Ernst; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

10.  Pharmacokinetics and bacteriologic efficacy of moxalactam, cefotaxime, cefoperazone, and rocephin in experimental bacterial meningitis.

Authors:  U B Schaad; G H McCracken; C A Loock; M L Thomas
Journal:  J Infect Dis       Date:  1981-02       Impact factor: 5.226

View more
  8 in total

1.  Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats.

Authors:  I A Bakker-Woudenberg; M T ten Kate; L Guo; P Working; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

2.  Application of mathematical model to experimental chemotherapy of fatal murine pneumonia.

Authors:  T Hishikawa; T Kusunoki; K Tsuchiya; Y Uzuka; T Sakamoto; T Nagatake; K Matsumoto
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

Review 3.  Evaluation of quinolones in experimental animal models of infections.

Authors:  W M Scheld
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 4.  Potential role of fluoroquinolones in the treatment of bacterial meningitis.

Authors:  J Modai
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 5.  The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.

Authors:  J M Hyatt; P S McKinnon; G S Zimmer; J J Schentag
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

6.  Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits.

Authors:  R Nau; T Schmidt; K Kaye; J L Froula; M G Täuber
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

Review 7.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

Review 8.  Prediction of brain delivery of ofloxacin, a new quinolone, in the human from animal data.

Authors:  J Kawakami; K Yamamoto; Y Sawada; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1994-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.